

Clinical Trial Activity in Ontario between 2015-2022

BRAIN AND/OR NERVES

Phase I using a diabetes drug for brain repair in children with Multiple Sclerosis: Toronto (Active)

Phase II using stem cells for Multiple Sclerosis: Complete

Phase II using a diabetes drug for brain repair in children with Cerebral Palsy: Toronto (Active)

Phase III using a diabetes drug to stimulate brain repair for malignant brain tumours: Complete

GENETIC DISORDERS

Phase I using genetically modified stem cells for Fabry Disease: Complete

BLOOD

Phase I using cell therapy to help patients recover from radiation/chemotherapies for the treatment of leukemia: Pending 2022-23

LIVER

Phase II-III using stem cells to induce tolerance in recipients of liver transplants: Ottawa and Toronto (Active)

JOINTS

Phase I-II using stem cells for knee osteoarthritis: Complete

Phase III using a cartilage tissue implant grown from patient's cells: Complete

BURNS

Phase I using stem cells developed from a patient's surgically removed burned tissue to improve wound healing: Toronto (Active)

MUSCLE

Phase I using a drug to restore muscle regeneration in children with Muscular Dystrophy: Pending 2022-23

HEART

Phase I using stem cells to repair heart damage: Pending 2022-23

Phase II using genetically modified stem cells following a heart attack: Complete

Phase II using stem cells for advanced heart failure with left ventricular assist device: Complete

LUNG

Phase I using stem cells for bronchopulmonary dysplasia in pre-term infants: Ottawa (Active)

Phase II using genetically modified stem cells for pulmonary arterial hypertension: London, Ottawa, Toronto and Hamilton (Active)

CRITICAL CARE

Phase I cell therapy for septic shock: Complete

Phase II cell therapy for septic shock: Pending 2021

Phase I cell therapy for COVID-19 related ARDS: Ottawa, Toronto, Montreal (Active)

All trials led by OIRM investigators.

All trials sponsored/funded by multiple partners: UHN, OHRI, SickKids, SRI, Dr. Gary Levy, Dr. Jas Chahal, Histogenics, CIHR, Stem Cell Network, Ozmosis Research Inc., Dr. Annetine Gelijns, National Heart, Lung and Blood Institute, Northern Therapeutics, Ontario Together and OIRM.

